Literature DB >> 1742505

Plasma osteocalcin levels in liver cirrhosis.

F Capra1, M Casaril, G B Gabrielli, A Stanzial, S Ferrari, G Gandini, G Falezza, R Corrocher.   

Abstract

Osteocalcin, a recently identified protein, is produced by osteoblasts in the bone tissue. Its plasma level is a good marker of bone metabolism and is reduced in the presence of 'osteodystrophia', commonly found in cholostatic liver diseases. We assayed plasma osteocalcin levels in 20 cirrhotic patients and compared the values with those of 22 healthy controls. In the same patients we also measured the liver function, clotting and mineral metabolism indexes and calcitonin plasma levels. Osteocalcin levels were significantly lower in liver disease patients than in controls (5.53 ng/ml S.D. 2.57 vs 7.79 ng/ml S.D. 2.23; p less than 0.01) and calcitonin plasma levels were much higher in cirrhotics (130.18 pg/ml S.D. 212.30 vs 28.9 pg/ml S.D. 13.09; p less than 0.05). We think that the low osteocalcin levels observed in cirrhotics may be a consequence of "hepatic osteodystrophy" due to low vitamin D and calcium plasma levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742505

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  4 in total

1.  Bone disorders in experimentally induced liver disease in growing rats.

Authors:  Viktória Ferencz; Csaba Horváth; Béla Kári; János Gaál; Szilvia Mészáros; Zsuzsanna Wolf; Dalma Hegedus; Andrea Horváth; Anikó Folhoffer; Ferenc Szalay
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

3.  Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?

Authors:  Ali Gur; Bünyamin Dikici; Kemal Nas; Mehmet Bosnak; Kenan Haspolat; Aysegul Jale Sarac
Journal:  BMC Gastroenterol       Date:  2005-09-19       Impact factor: 3.067

4.  Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats.

Authors:  F A Pereira; R Mattar; I Facincani; H L A Defino; L N Z Ramalho; V Jorgetti; J B Volpon; F J A de Paula
Journal:  Braz J Med Biol Res       Date:  2012-09-11       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.